Redx Pharma plc Exercise of Options and Total Voting Rights (9673M)
27 Septiembre 2021 - 01:59AM
UK Regulatory
TIDMREDX
RNS Number : 9673M
Redx Pharma plc
27 September 2021
REDX PHARMA PLC
("Redx" or "the Company")
Exercise of Options and Total Voting Rights
Alderley Park, 27 September 2021, Redx Pharma plc (AIM: REDX),
the drug discovery and development company focused on cancer and
fibrosis, announces the exercise of share options by a former
employee of the Company over 500,000 new ordinary shares of 1 pence
each in the capital of the Company ("Ordinary Shares") at exercise
prices of 22 pence (166,666 shares), 33 pence (166,667 shares) and
50 pence (166,667 shares) per share respectively.
Application has been made to the London Stock Exchange for the
500,000 new Ordinary Shares to be admitted to trading on AIM and
admission is expected to occur on or around 8.00am on 28 September
2021. The new Ordinary Shares will rank pari passu with the
existing Ordinary Shares in issue.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency
Rules, following the above issue of equity, the issued share
capital of the Company will comprise 275,282,205 Ordinary Shares.
The above figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in, the
Company, under the Disclosure Guidance and Transparency Rules.
For further information, please contact:
Redx Pharma Plc T: +44 1625 469 918
Peter Presland, Interim Chairman
Lisa Anson, Chief Executive
Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 203 368 3550
Matt Davis/Adam Dawes
WG Partners LLP (Joint Broker) T: +44 20 3705 9330
Claes Spång/ David Wilson
Panmure Gordon (UK) Limited (Joint Broker) T: +44 20 7886 2500
Rupert Dearden/Freddy Crossley/Emma Earl
FTI Consulting T: +44 20 3727 1000
Simon Conway/Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and
development of novel targeted medicines for the treatment of cancer
and fibrotic diseases, aiming initially to progress them to
clinical proof of concept, before evaluating options for further
development and potential value creation. Redx's lead oncology
asset, the Porcupine inhibitor RXC004, is expected to commence a
Phase 2 programme in H2 2021. The Company's selective ROCK2
inhibitor, RXC007, is in development for idiopathic pulmonary
fibrosis and commenced a Phase 1 clinical study in June 2021 for
which results are expected in 2022.
The Company has a strong track record of discovering new drug
candidates through its core capability of converting medicinal
chemistry insights into differentiated and commercially attractive
drug candidates, with five proprietary or partnered assets in late
pre-clinical or clinical development. One of those assets, a BTK
inhibitor - pirtobrutinib/LOXO-305 - was sold to Loxo Oncology (now
Eli Lilly) and is currently in Phase 3 clinical studies in chronic
lymphocytic leukaemia. In addition, Redx has forged pre-clinical
asset partnerships with other blue chip companies including
AstraZeneca and Jazz Pharmaceuticals.
To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPURGBUPGGQC
(END) Dow Jones Newswires
September 27, 2021 02:59 ET (06:59 GMT)
Redx Pharma (LSE:REDX)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Redx Pharma (LSE:REDX)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024